BioCryst Pharmaceuticals, Inc. (BCRX)
7.36
+0.04
(+0.55%)
USD |
NASDAQ |
Nov 20, 10:00
BioCryst Pharmaceuticals Free Cash Flow : 348.92M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | 348.92M |
| June 30, 2026 | 356.23M |
| March 31, 2026 | 293.05M |
| December 31, 2025 | 327.41M |
| September 30, 2025 | 47.64M |
| June 30, 2025 | 15.50M |
| March 31, 2025 | -27.01M |
| December 31, 2024 | -53.14M |
| September 30, 2024 | -58.08M |
| June 30, 2024 | -86.59M |
| March 31, 2024 | -103.95M |
| December 31, 2023 | -97.31M |
| September 30, 2023 | -112.21M |
| June 30, 2023 | -123.95M |
| March 31, 2023 | -132.67M |
| December 31, 2022 | -163.20M |
| September 30, 2022 | -172.39M |
| June 30, 2022 | -163.42M |
| March 31, 2022 | -161.64M |
| December 31, 2021 | -144.54M |
| September 30, 2021 | -155.77M |
| June 30, 2021 | -170.56M |
| March 31, 2021 | -175.44M |
| December 31, 2020 | -137.73M |
| September 30, 2020 | -103.46M |
| Date | Value |
|---|---|
| June 30, 2020 | -92.76M |
| March 31, 2020 | -86.23M |
| December 31, 2019 | -89.93M |
| September 30, 2019 | -103.49M |
| June 30, 2019 | -110.84M |
| March 31, 2019 | -100.33M |
| December 31, 2018 | -92.93M |
| September 30, 2018 | -79.48M |
| June 30, 2018 | -57.02M |
| March 31, 2018 | -52.63M |
| December 31, 2017 | -41.47M |
| September 30, 2017 | -36.69M |
| June 30, 2017 | -41.81M |
| March 31, 2017 | -45.14M |
| December 31, 2016 | -58.72M |
| September 30, 2016 | -71.74M |
| June 30, 2016 | -66.80M |
| March 31, 2016 | -36.05M |
| December 31, 2015 | -18.24M |
| September 30, 2015 | -13.32M |
| June 30, 2015 | -9.151M |
| March 31, 2015 | -33.98M |
| December 31, 2014 | -38.66M |
| September 30, 2014 | -29.22M |
| June 30, 2014 | -28.51M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Halozyme Therapeutics, Inc. | 885.88M |
| Neurocrine Biosciences, Inc. | 973.10M |
| Agenus, Inc. | -103.86M |
| Amgen, Inc. | 9.581B |
| Anika Therapeutics, Inc. | 2.295M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 32.69M |
| Cash from Investing (Quarterly) | -78.88M |
| Cash from Financing (Quarterly) | -11.78M |
| Free Cash Flow Per Share (Quarterly) | 0.1213 |
| Free Cash Flow to Equity (Quarterly) | 40.90M |
| Free Cash Flow to Firm (Quarterly) | 53.27M |
| Free Cash Flow Yield | 18.51% |